Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;131(3):210-4.
doi: 10.1016/j.mad.2010.01.009. Epub 2010 Feb 6.

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease

Justus C Dachsel  1 , Kenya Nishioka, Carles Vilariño-Güell, Sarah J Lincoln, Alexandra I Soto-Ortolaza, Jennifer Kachergus, Kelly M Hinkle, Michael G Heckman, Barbara Jasinska-Myga, Julie P Taylor, Dennis W Dickson, Rachel A Gibson, Faycal Hentati, Owen A Ross, Matthew J Farrer
Affiliations

Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease

Justus C Dachsel et al. Mech Ageing Dev. 2010 Mar.

Abstract

LRRK2 mutations are recognized as the most frequent genetic cause of both familial and sporadic parkinsonism identified to date. A remarkable feature of this form of parkinsonism is the variable penetrance of symptom manifestation resulting in a wide range of age-at-onset in patients. Herein we use a functional approach to identify the Lrrk1 protein as a potential disease modifier demonstrating an interaction and heterodimer formation with Lrrk2. In addition, evaluation of LRRK1 variants in our large Lrrk2 p.G2019S-parkinsonism series from a Tunisian (n=145) identified a missense mutation (p.L416M) resulting in an average 6.2 years younger age at disease onset. In conclusion we show that the interaction of Lrrk1-Lrrk2 can form protein dimers and this interaction may influence the age of symptomatic manifestation in Lrrk2-parkinsonism patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of Lrrk1 and Lrrk2 domain structures: ARM= armadillo, ANK= ankyrin, LRR= leucine-rich, ROC= Ras of complex, COR= C-terminus of ROC.
Figure 2
Figure 2
Absolute LRRK1 and LRRK2 mRNA expression levels in human control brain. Copy numbers for LRRK1 and LRRK2 were calculated by comparison to a standard curve of co-amplified plasmids encoding full length Lrrk1 or Lrrk2 proteins.
Figure 3
Figure 3
Lrrk1 and Lrrk2 proteins interact in vitro: A. Co-immunoprecipitation of full length Lrrk1-V5 with FLAG-Lrrk2 in HEK293T cells. The left panel shows the presence of Lrrk1-V5 but not LacZ-V5 in the FLAG-Lrrk2 immunoprecipitate (IP). The inputs on the right panel represent the amounts of transfected proteins introduced in the immunoprecipitation assay.B. Co-precipitation of Lrrk2-V5 with FLAG-Lrrk1. Successful co-pull-down of Lrrk2-V5 occurs only in the presence of FLAG-Lrrk1 (IP left; Inputs right). A stronger detection signal was observed when Lrrk2 was used to pull-down Lrrk1 than vice versa, which may indicate a higher affinity of Lrrk2 for Lrrk1, whereas Lrrk1 might preferentially engage in interactions with other proteins. However as co-immunoprecipitation assays do not provide a reliable quantitative assessment of binding affinities this warrants further investigation.
Figure 3
Figure 3
Lrrk1 and Lrrk2 proteins interact in vitro: A. Co-immunoprecipitation of full length Lrrk1-V5 with FLAG-Lrrk2 in HEK293T cells. The left panel shows the presence of Lrrk1-V5 but not LacZ-V5 in the FLAG-Lrrk2 immunoprecipitate (IP). The inputs on the right panel represent the amounts of transfected proteins introduced in the immunoprecipitation assay.B. Co-precipitation of Lrrk2-V5 with FLAG-Lrrk1. Successful co-pull-down of Lrrk2-V5 occurs only in the presence of FLAG-Lrrk1 (IP left; Inputs right). A stronger detection signal was observed when Lrrk2 was used to pull-down Lrrk1 than vice versa, which may indicate a higher affinity of Lrrk2 for Lrrk1, whereas Lrrk1 might preferentially engage in interactions with other proteins. However as co-immunoprecipitation assays do not provide a reliable quantitative assessment of binding affinities this warrants further investigation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008;70:1456–1460. - PMC - PubMed
    1. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a casecontrol genetic study. Lancet Neurol. 2008;7:591–594. - PubMed
    1. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007;3:e82. - PMC - PubMed
    1. Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L, Farrer MJ. Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord. 2007;13:382–385. - PMC - PubMed
    1. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15:223–232. - PubMed

Publication types